Pharma R&D Today

Seeing Research Through a Scientist’s Eyes

Posted on July 26th, 2017 by Dr. Anton Yuryev

If it’s your job to create and maintain information solutions designed to be used by scientists, it probably helps if you have real-world experience conducting scientific research, right? Continue reading “Seeing Research Through a Scientist’s Eyes” »

Hopes, Issues, and Concerns in Tackling the Challenge of Dementia

Posted on July 24th, 2017 by Dr Andrew A. Parsons

With recent failures of large Phase 3 studies targeting the amyloid pathways, there is perhaps a need for some good news for scientists, clinicians, health services and the general public. Recently, there was some good news in the media. Continue reading “Hopes, Issues, and Concerns in Tackling the Challenge of Dementia” »

Maryland Attempts to Control Drug Prices

Posted on July 21st, 2017 by Betsy Davis

Consumer concerns over the price of drugs remain high, so it’s not surprising that Maryland recently passed a bill aimed at controlling costs. Continue reading “Maryland Attempts to Control Drug Prices” »

Wearables in Clinical Trials: Many Benefits, and One Big Challenge

Posted on July 19th, 2017 by Tim Hoctor

The rapid development of wearable technology has the power to be a game-changer in many areas, including pharmaceutical R&D. Its most obvious use for pharma is in clinical trials, where recruiting is a frequent challenge, as is getting study participants to adhere to their therapeutic regime. Continue reading “Wearables in Clinical Trials: Many Benefits, and One Big Challenge” »

The certainty of uncertainty

Posted on July 17th, 2017 by Dr Andrew A. Parsons

The recent election results in France and the UK once again show that a week is a long time in politics. Who would have thought when the UK voted to Brexit that Emmanuel Macron would sweep into power following the creation of his new political party in April 2016? Continue reading “The certainty of uncertainty” »

Precise Medicines: Matching Patients with the Most Effective Drugs

Posted on July 14th, 2017 by Dr. Anton Yuryev

Precision medicine is making us re-think the way we treat disease. Rather than selecting therapies based solely on the disease itself, doctors are increasingly considering the patient’s unique genomic and molecular make-up when determining treatment. Continue reading “Precise Medicines: Matching Patients with the Most Effective Drugs” »

About this Blog

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.